Accessibility Menu
Arrow-Thin-Down
S&P 500
6,632.19
-0.6%
-40.43
Arrow-Thin-Down
DJI
46,558.47
-0.3%
-119.38
Arrow-Thin-Down
NASDAQ
22,105.36
-0.9%
-206.62
Arrow-Thin-Down
Bitcoin
$73,226.00
+2.1%
+$1,481.08
Arrow-Thin-Down
AMZN
$207.70
-0.9%
-$1.83
Arrow-Thin-Down
GOOG
$301.52
-0.6%
-$1.69
Arrow-Thin-Down
META
$613.19
-3.8%
-$24.45
Arrow-Thin-Down
MSFT
$395.54
-1.6%
-$6.32
Arrow-Thin-Down
NVDA
$180.28
-1.6%
-$2.87
Arrow-Thin-Down
TSLA
$391.54
-0.9%
-$3.47
Most Active StocksDaily Stock GainersDaily Stock Losers

4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

By Neil Rozenbaum – Jan 16, 2024 at 10:30AM EST

In this video, I will go over four healthcare stocks that represent different exposures to the healthcare industry. One of the companies I cover happens to be the fifth-largest player in the healthcare plans industry, Humana (HUM +1.07%).

*Stock prices used were from the trading day of Jan. 12, 2024. The video was published on Jan. 16, 2024.

Read Next

Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbCellera Biologics. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Stocks Mentioned

Humana Stock Quote
Humana
NYSE: HUM
$165.26
(+0.97%)+$1.59
Centene Stock Quote
Centene
NYSE: CNC
$34.48
(-0.26%)-$0.09
Halozyme Therapeutics Stock Quote
Halozyme Therapeutics
NASDAQ: HALO
$63.66
(+0.16%)+$0.10
AbCellera Biologics Stock Quote
AbCellera Biologics
NASDAQ: ABCL
$3.50
(+0.86%)+$0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services